We know how important it is to get medicines to the people who need them and providing those medicines is at the center of what we do
January 24, 2024
Share this article
In 2012, MSD unexpectedly became the sole manufacturer of OncoTICE® in many countries around the world. Increasing global demand has outpaced our current maximum manufacturing capabilities. In recognition of the medical need for this product, MSD continues to operate at maximum production capacity. Due to the increasing global demand, MSD has been experiencing a supply shortage for OncoTICE.
In October 2020, we announced our plans to construct a new manufacturing facility in Durham, North Carolina, U.S., to significantly expand our production capacity for OncoTICE. This investment reaffirms our longstanding commitment to producing this medicine, and all our medicines, for patients who need them.
If patients have questions regarding OncoTICE, they should speak with their physicians. Additional information related to the shortage, current allocation practices, and our efforts to increase supply, including construction of a new manufacturing site, is below.
FAQs: supply & availability of OncoTICE
What is the cause of the shortages and backorders for OncoTICE?
Since 2012, when MSD unexpectedly became the sole manufacturer of OncoTICE in many countries around the world, increasing global demand has outpaced our current maximum manufacturing capabilities. While the company has many years of experience producing OncoTICE, this medicine has a lengthy and inherently complex manufacturing process.
Prior to 2012, additional manufacturers supplied the U.S. market with OncoTICE, with MSD providing 30-40% of overall U.S. supply. As other manufacturers exited the U.S. market in 2012, MSD became the sole supplier to the U.S. and increased production of OncoTICE to the full extent of MSD’s current manufacturing capacity. These efforts enabled MSD to double supply of OncoTICE to the U.S. market despite being the only manufacturer, in recognition of the medical need for this product.
Can you provide an update on the new facility?
MSD is working to complete this project and meet patient needs in as timely a manner as possible. While this commitment is an important step in making sure that adequate supply of OncoTICE is available, completing construction, inspection, and regulatory approvals of a manufacturing facility may take approximately five to six years in total.
Construction is well underway, barring any unforeseen circumstances, the new facility is on track to the previously announced timeline and will be completed by late 2025 to late 2026. Supply will gradually increase over time following local market review and approvals.
Once this new facility is fully operational, we expect to triple our current manufacturing capacity of OncoTICE. We anticipate that this will meet the needs of physicians and their patients for the foreseeable future. The investment in this new manufacturing facility reaffirms MSD’s longstanding commitment to producing this medicine for patients.
Can you please describe how the allocation process works outside the U.S.?
MSD allocates available supply among markets based on historical demand patterns. This process is designed to proportionally allocate OncoTICE to minimize disruption to patient care as much as possible.
Where can I find more information about the availability of OncoTICE??
Patients:
Patients should reach out to their physician, as they are in the best position to answer questions about the availability of the medicine in their practice, and can inquire about the quantity and timing of product availability with their supplier.
Health care professionals:
Health care professionals with questions regarding allocation should contact their wholesaler or distributor.
How one woman embraced life, marriage and motherhood despite her cervical cancer diagnosis and its return
January 11, 2024
Share this article
Several years ago, Christine Granado was living happily in New Jersey with her fiancé and then-9-year-old son, but she felt something wasn’t right.
In the span of a year, she lost three pregnancies. The first miscarriage came as a total shock. With the second, she felt confused. After the third, she was afraid something was terribly wrong. She decided to go for a routine checkup. While undergoing a series of tests ordered by her OB-GYN, she got surprising news: she was diagnosed with stage IIB squamous cell cervical cancer that had spread to her lymph nodes. At just 28, Christine said she felt disbelief.
“How can I have cancer at this age?” she asked herself. “I remember peeking through my bangs, feeling like I was trying to hide behind them.”
Young women are at risk for cervical cancer, too
Granado wasn’t alone in asking herself that question. Cervical cancer is more likely to affect women under 45 globally than most other cancers. In 2020, it was estimated that about 604,127 women were diagnosed with cervical cancer worldwide and about 341,831 women died from the disease. Screenings may help to detect cervical changes before they become cancerous. In several western countries where screenings are routinely conducted, the incidence rates of cervical cancer have decreased by 50% or more over the past 50 years.
Beginning her cancer treatment journey
Granado started treatment as soon as possible. She was prepared for physical side effects but was overwhelmed by the other changes that soon followed, including how she felt about losing her fertility. She and her partner discussed preserving her eggs but decided against it as doing so would have delayed her treatment.
Granado’s cancer went into remission for three years, and she found joy again: She and her fiancé got married and decided to have a baby via surrogate.
The shock of a recurring cancer diagnosis
Then, soon before her son was born, Granado started having unexplained chest pains. A CT scan found enlarged lymph nodes. She was diagnosed with metastatic cancer.
“When I got the recurrence diagnosis, I was devastated. It was hard to hear, but it motivated me to finish things, to contact a lawyer and get things in my kids’ names — to think about life after me,” she said.
It also motivated her to continue with more treatments. During her second round of treatment, Granado was able to welcome her new son. When she saw him, she took him in her arms: “I bawled my eyes out.”
A focus on mental health
In addition to her son’s arrival, Granado said a focus on herself has sharpened her resolve to live her best life. When the cancer came back, she grieved for her life. She would cry and sleep all day. Her depression stopped her from enjoying precious time with her family.
“The most disabling thing I dealt with was the depression,” she said. “There were days when I would feel physically OK, but I’d still stay in bed all day.” Thankfully, Granado had the support of a psychologist and a psychiatrist who helped her feel well again.
Cervical cancer won’t stop her from living her best life
Granado has been able to complete a master’s degree in health leadership, and her family has a new border collie named Harry. Even everyday activities like going to the hardware store and winding down with a book mean so much more now. She appreciates the small details, like watching TV with her son on the couch.
“Life has been amazingly boring,” she says. “In a good way.”
Granado said she hopes her story will inspire women and give them hope that there’s so much life to be lived — including the boring moments — in the face of a cancer diagnosis.
Empowering others to speak up about HPV-related cancers
The impact of Gina’s diagnosis inspired her to help others prioritize their health
January 9, 2024
Share this article
youtube
https://www.youtube.com/watch?v=eKsXu9JY2gE
:
After 20 years of normal cervical screenings,* Gina Esposito was confident her next routine screening wouldn’t be any different. So, when she was diagnosed with human papillomavirus (HPV)-related cervical precancer at 47 years old, she was surprised.
“The sinking feeling I had when I received my diagnosis was intense because I wasn’t expecting it,” she said.
*A cervical screening, often referred to as a pap test or pap smear, looks for precancers or cell changes that might become cervical cancer if not treated appropriately.
The impact of HPV-related cancers and diseases
More than 80% of cervical cancers are associated with HPV. For most people, HPV clears on its own. But for those who don’t clear the virus, it could cause certain cancers and diseases.
After her diagnosis, Esposito underwent a procedure to remove the abnormal cells from her cervix. When a follow-up test showed that there were still some abnormal cells present, she consulted with a doctor and decided to get a hysterectomy.
At first, she felt embarrassed by her diagnosis. As she started to share her story, she noticed that others felt ashamed to speak about HPV-related cancers and diseases. She knew something had to change.
“I have a newfound responsibility to take the stigma away, to say ‘the shame has to go away,’ whether you’re a woman or a man,” Esposito said.
Throughout her experience, she says her daughter has been a source of strength.
“You don’t want your child to be without you or to experience the loss of a parent. You want to be around for all of their milestones and they want you around,” Esposito said. “So, she keeps me motivated because there’s an expectation that mom’s going to be around.”
“I try to be a positive disruptor in this space and normalize it so that people go for early screenings and routine screenings and that they get treatment if they need it.”
— Gina Esposito
The importance of routine care
In some ways, Esposito considers herself lucky. Her commitment to prioritizing routine care helped her catch her disease early.
“I’m so glad I took the time to go to my screening – it helped catch my disease early,” she said.
Esposito is working to ensure her daughter also prioritizes getting routine care and understands the value of prioritizing her health, especially as she approaches adulthood.
“She knows you need to own your own health because no one else is going to do it for you,” she said. Esposito encourages colleagues across our company to prioritize their health, too.
Esposito plans to continue helping men and women feel comfortable discussing HPV-related disease and get the preventative care they need.
“When I talk with others, I focus on what happened to me so they can use it as an example,” Esposito said. “I get people emailing me, texting me, going, ‘I’m going to make my appointment today.’ And if we can have one person that we get early, then my job is done.”
Biomarker testing may help inform treatment decisions in certain cancers
An oncologist explains why cancer biomarkers may provide more precise information about a person's cancer
January 4, 2024
Share this article
Over the past 20+ years, there’s been an evolution in how we think about cancer. Cancer biomarkers — substances produced by tumor cells that reflect unique features of a tumor — can change the approach to certain cancers.
Advances in biomarker testing may help inform treatment decisions
It wasn’t long ago when conversations were about simply “breast cancer” or “lung cancer.” Now, physicians can get a lot more precise.
“We’ve come to understand that two people with the same type of cancer may have differences in the specific changes in the genes, proteins and other substances that may allow cancer cells to grow and spread.”
Dr. Scott Pruitt Associate vice president, early-stage development, clinical oncology, MSD Research Laboratories
“The field of breast cancer research was arguably the first to realize that there are multiple cancer subtypes and that biomarker testing could help inform therapy,” said Pruitt.
In the treatment of breast cancer, understanding various tumor biomarkers and pairing that understanding to help guide selection of relevant medicines has helped physicians evaluate potential treatment approaches. And the same is true in lung cancer where understanding tumor biomarkers has been used to help guide therapy aimed at targeting certain genetic mutations.
Biomarkers may help us understand a cancer better and how to approach it. That’s why biomarker testing may be an important next step after a cancer diagnosis.
Key terms to know:
Biomarker: a measurable indicator of a biological state or condition found in blood or tissues.
Biomarker testing: medical tests to look for measurable indicators (genes, proteins and other substances) that may provide information about a biological state or condition.
Biopsy: the removal of cells or tissue for examination.
Genetic testing: medical tests to look for certain mutations in a person’s genes that may be a sign of a disease or condition.
Biomarker testing after a cancer diagnosis
Blood test
Biopsy of the tumor
Testing for proteins and/or genes to look for known biomarkers
Biomarker testing and genetic testing may enable detailed characterization of some cancers
Some biomarker tests can find inherited genetic changes that you may have been born with that may increase your risk of cancer or other diseases. Genetic testing might help determine if you have certain mutations (for example, the BRCA gene) which could help inform treatment options.
MSD has been at the forefront of research to advance the understanding of biomarkers for certain cancers.
"We're fully invested in leveraging biomarker data to help inform cancer care."
— Dr. Scott Pruitt
“Across our oncology studies in every phase of development, we continue to incorporate multiple biomarker approaches to more fully understand biology as well as identify new targets of interest,” Pruitt said.
Discussing biomarker testing with a health care provider
If you’ve been diagnosed with cancer, it’s important to ask your doctor about biomarker testing. Start with these questions which may help you prepare for conversations with your doctor:
Is biomarker testing appropriate for the type of cancer that I have?
If there’s a chance my cancer was caused by an inherited risk factor, should I undergo further testing?
The impact of RSV: a father’s story and call for prevention
When his own daughters became sick, one colleague saw firsthand the need to protect kids from RSV
December 14, 2023
Share this article
Frederik Tack, an MSD employee and devoted father, has spent over a decade working in infectious diseases. So, when his daughters both contracted respiratory syncytial virus (RSV) infections, the impact of his work hit especially close to home.
RSV is a contagious, widespread seasonal infection that is similar to the flu. While people infected with RSV are usually contagious for about three to eight days, infants can continue to spread the virus even after they stop showing symptoms for up to one month.
“Being quite familiar with infectious diseases, I knew the basics of RSV and that almost all children contract it at least once before they’re 2 years old,” said Tack, executive director for our company in France.
"For most healthy children, RSV is like a cold, but for some it can become complicated. And unfortunately, my family witnessed these complications firsthand."
Frederik Tack
Executive director, France
Tack’s eldest daughter, Oriane, developed RSV and bronchiolitis at just 1 year old, leading to dehydration and a brief hospital stay for one night. A few years later, his second daughter, Anora, contracted the virus twice and experienced even more severe complications, including pneumonia that required a week-long stay in the hospital. Fortunately, Tack’s daughters both recovered following their hospital visits and have not experienced any long-term effects of the virus.
“As you can imagine, it was a pretty stressful time,” he said. “After experiencing it myself, my hope is that other parents won’t have to go through such an uncertain and frightening experience.”
The impact of RSV on infants and families
Grateful that his daughters are now healthy and fully recovered, Tack is acutely aware of the near- and long-term complications many other children may face with RSV. RSV can impact both children and adults but is particularly threatening for infants, who may not be able to fight the virus on their own. It can potentially lead to more serious respiratory conditions like asthma, bronchiolitis or pneumonia.
“In the first years that followed, we often held our breath, hoping those experiences with RSV wouldn’t repeat themselves or provoke long-term complications of other respiratory conditions,” Tack said.
A closer look at RSV
— RSV is contagious and can be spread through virus droplets when an infected person coughs or sneezes, or through direct contact with the virus, like kissing the face of a child with RSV.
— The virus can cause cold-like symptoms, including a runny nose, fever, coughing and wheezing.
— It’s a leading cause of infant hospitalizations globally.
~3.6M
Estimated hospitalizations globally each year in children under 5 years old*
~101K
Estimated deaths caused by RSV globally each year in children under 5 years old*
~95%
An estimated >95% of RSV infections and >97% of RSV-related deaths globally occur in resource-limited countries*
*Data based on 2019 estimates.
There’s a widespread need for protection for both healthy and high-risk infants from RSV globally, including in resource-limited countries where RSV represents a substantial burden of disease. And during RSV season, the impact can be even greater. RSV can put a significant strain on the health care system, but most importantly, it impacts families who want to help protect their children and keep them healthy.
Tack said he takes great pride in being part of a company with over 130 years of innovative work dedicated to reducing the devastating toll of certain infectious diseases around the world.
“Nobody wants to see their children suffering with little that you can do to help them,” said Tack.
“I’m inspired by the ongoing commitment and dedication within the public health space to help address these diseases through scientific innovations.”
Stomach cancer: understanding the signs and symptoms
Learn more about stomach cancer risk factors and our commitment to patients
November 22, 2023
Share this article
What causes stomach cancer?
Stomach cancer, also called gastric cancer, occurs when malignant (cancer) cells form in the lining of the stomach. The most common form of stomach cancer is adenocarcinoma, which develops when glandular cells in the innermost lining of the stomach grow uncontrollably.
How common is stomach cancer?
Worldwide, there were more than one million patients diagnosed with stomach cancer and an estimated 768,793 patient deaths from the disease in 2020.
Who’s at risk for stomach cancer?
Anybody can be diagnosed with stomach cancer; however, it’s almost twice as common in men, and most people are older than 55 when diagnosed.
You may also have a higher chance of developing stomach cancer if you:
Have had a Helicobacter pylori (H pylori) infection, which is an infection of the stomach, that commonly causes stomach ulcers.
Are overweight or obese.
Have a diet high in salty, smoked, pickled or salt-preserved foods and/or high in processed or grilled meats. Eating few or no fruits likely increases the risk of stomach cancer.
Drink three or more alcoholic beverages per day.
Use tobacco.
Have had previous stomach surgery or health conditions, such as low stomach acid and bile reflux.
What are the signs and symptoms of stomach cancer?
Early-stage stomach cancer rarely causes symptoms, which is why most cases are diagnosed after the cancer has spread (metastasized) to other parts of the body.
Fatigue.
Heartburn, indigestion and anemia.
Swelling or fluid build-up in the abdomen, jaundice or weight loss without trying.
Poor appetite, abdominal pain, nausea, vomiting with or without blood or feeling full after a small meal.
Blood in stool.
Any of these warning signs should be discussed with a doctor, especially if you feel you’re at risk for stomach cancer.
If you have questions about stomach cancer and its symptoms, it’s important to discuss these with your doctor. Some questions to ask your doctor may include:
Q: Can young people be diagnosed with stomach cancer? A: While the majority of stomach cancer patients are over 55 years old, it’s important to know that younger people can also be diagnosed with stomach cancer. Nearly 5% of patients diagnosed with stomach cancer are under 40 years old.
Q: How do doctors determine the stage of a stomach cancer? A: When someone is diagnosed with stomach cancer, doctors will conduct tests, such as endoscopic procedures, biopsies and imaging, to help determine how far the cancer has spread. This is called staging. By staging stomach cancer, doctors can determine how serious the cancer is and the best way to treat it.
“When facing a stomach cancer diagnosis, some patients may have existing misconceptions about the disease or be unsure about what this diagnosis will mean for them."
— Dr. Pooja Bhagia
GI clinical research scientist, MSD Research Laboratories
“Having an open conversation with your doctor about your questions and concerns may help reduce worry and help you understand what to expect in your cancer journey,” she added.
Harnessing innovative technology in drug discovery
MSD scientists explain how new technologies can accelerate the drug discovery process as we use the power of leading edge science to save and improve lives
November 16, 2023
Share this article
youtube
https://www.youtube.com/watch?v=SUBduOKtrnE
:
Our scientists are leveraging state-of-the-art capabilities to discover novel molecules that may lead to the medicines of tomorrow.
MSD Research Laboratories (MRL) scientists evaluate hundreds to thousands to up to billions of compounds to find a starting point for a new drug candidate. It all starts with identifying a target — usually a protein — that’s intrinsically associated with a particular disease and can be pharmacologically modulated. That’s where innovative tools like structure-based design, high-throughput screening and high-throughput experimentation, coupled with robotics, artificial intelligence and machine learning can make a huge difference in progressing the work. And once a lead molecule is identified, cryogenic electron microscopy (cryo-EM) as an emerging structural method can be used to understand and improve how a molecule interacts with the protein target.
Utilizing the latest technologies and diligent work by teams of highly skilled and experienced scientists can potentially accelerate the discovery of new medicines for patients in need.
“We have an incredibly creative, smart and hardworking workforce. It’s an absolute pleasure to be part of that and to have access to the resources necessary for making scientific breakthroughs.”
Once you have CMV, it stays in your body for life.
November 14, 2023
Share this article
If you knew that on average, an estimated 83% of the global population has a certain virus that stays in their bodies for life once they’re infected, would you want to know more?
The truth is, such viruses do exist, including one called “cytomegalovirus” (CMV).
What is cytomegalovirus (CMV)?
CMV is a common virus related to the herpes virus, and it can be spread through bodily fluids, like saliva, tears, breast milk or semen. In healthy individuals, CMV can cause no or few symptoms and no long-term health consequences. They may never know they were infected in the first place. Once a person is infected, the virus can remain dormant in the body for years.
However, if your immune system is weakened, there’s a chance that CMV infection (either an initial CMV infection or a reactivation of latent CMV) can lead to symptomatic disease and more serious symptoms affecting the eyes, lungs, liver and other organs.
Who does CMV impact?
Everyone from newborns to adults can pass CMV to others.
On average, an estimated 83% of the global population is infected with CMV
CMV in pregnancy
CMV can be passed to babies during pregnancy through the placenta. When this happens, the baby is born with congenital CMV. Most babies with congenital CMV don’t experience health problems. But some babies born with congenital CMV will have symptoms or other long-term health challenges.
Babies born with congenital CMV can experience hearing loss, intellectual disability or seizures
CMV in cancer patients
Cancer patients who have CMV may be more vulnerable to viral reactivation when receiving chemotherapy treatments, which may weaken the immune system.
CMV in transplant patients
People receiving transplants are especially vulnerable when it comes to CMV infection.
For example, patients with blood or other cancers who undergo a bone marrow transplant will take medicines to prevent their bodies from rejecting donated tissue. These medicines can impact their immune systems, making it harder for them to fight off CMV or other infections. For people who already have CMV in their bodies, this can leave them vulnerable to CMV reactivation.
CMV reactivation has been shown to occur in ~30-65% of allogeneic* bone marrow transplant recipients who are CMV-positive
*using stem cells from another person (donor)
Transplant recipients can also get CMV from organs donated by people with CMV. Patients undergoing a solid organ transplant (like a liver or kidney transplant) that are negative for CMV face the highest risk of CMV disease when their organ donor has CMV. In 2021, ~92,532 kidney transplants were performed globally.
CMV infection after kidney transplant can increase patients’ risk of experiencing organ rejection
Managing CMV
CMV is a common virus, and for most people, it’s not a serious health problem. However, in specific vulnerable groups like transplant recipients, complications from CMV infection can be serious. It’s important that people are aware of the virus and the impact it can have.
Want to learn more about CMV?
If you have questions about CMV and its potential risks, talk to your health care provider today.
Meet these young advocates helping to lead the response to HIV around the world
November 13, 2023
Share this article
HIV remains a global pandemic. In 2022 alone, an estimated 1.3 million people worldwide were newly diagnosed with HIV.
MSD has been committed to advancing science for the treatment and prevention of HIV for more than 35 years, but we know it takes all of us to make a difference for the HIV community.
And that’s just what these International AIDS Society (IAS) Young Leaders are doing. In 2022, our company was proud to be one of the groups to support 11 Young Leaders to co-create the Youth Hub — a youth-led networking platform that empowers young change-makers living with and affected by HIV to lead in the HIV response. They’re an inspiring group of advocates with different backgrounds and experiences in the response to HIV, each striving to empower and educate others from their respective corners of the globe.
Let’s meet some of these young change-makers.
Norman Chong | Malaysia
Norman Chong is using their gift of storytelling to encourage young people across the world to ask “Why?” Chong has been working to develop a solution-oriented platform to help address gaps in the HIV response for young people in Malaysia.
With their platform, called “We Ask the Y (WAY)”, Chong aims to provide tools for young people living with and affected by HIV to learn and network in support of social health, as well as economic and political justice. Chong also trains young researchers to translate and communicate findings into evidence-informed policies and practices to address barriers to health care for young people.
“If I have anything at all, it’s anchored on moving the dial with the question, “Why?”, and advocating for health care to be accessible to all, for policies designed to protect and empower, and never to divide and conquer.”
Norman Chong
Linda Joseph Robert | Uganda
Dismantling HIV stigma to support young people is the motivation for everything Linda Joseph Robert does. As a youth advocate, he helps to promote increased access to quality adolescent sexual and reproductive health services for young people through peer support interventions, community engagements and strategic partnerships. His passion for youth advocacy, activism and HIV-related programming came to life when he led a campaign to help reduce HIV stigma and discrimination during the COVID-19 pandemic.
As a young person living with HIV, Robert is driven to help increase access to HIV prevention, treatment and care services. Robert has held leadership positions including the role of youth advocate at AIDS Healthcare Foundation-Uganda Cares, and serves as a U=U Africa Forum Ambassador in Uganda.
“I’m motivated by the progress that has been made in the HIV field and excited to be part of the next generation of HIV professionals who will continue the journey toward ending the AIDS pandemic, where no one is left behind.”
Linda Joseph Robert
Elizabeth Onyango | Kenya
UKIMWI UNAUA is a term Elizabeth Onyango and others in Kenya know too well. Translated to “HIV kills,” this phrase influenced Onyango’s perception of HIV at a young age — as the messaging around HIV in her country was mostly about death and fear. Growing up, she lost close family and friends to HIV and saw how cultural beliefs and practices exposed young women and girls to HIV. It wasn’t until she went to high school that Onyango learned about ways to protect against HIV, which helped reduce the fear she grew up with — and sparked an interest in HIV prevention.
After high school, she volunteered at a female sex worker-led organization that champions human and health rights of sex workers. Today, Onyango continues to encourage young women to take action to ensure they have a say in decisions about their health.
“My goal is to champion meaningful engagement of women and girls in HIV prevention and advocate for structural changes to improve the quality of life of women living with HIV.”
Elizabeth Onyango
Isaac Ogunkola | Nigeria
A background in public health has given Isaac Ogunkola deep insight into the world of infectious diseases, especially HIV. His passion for HIV advocacy became clear after volunteering to encourage harm reduction for people who use drugs and promote sexual and reproductive health and rights programming for homeless children, refugees and young people.
Having witnessed young people in his community die as a result of drug overdose and HIV, Ogunkola is committed to unifying public health, harm reduction and human rights. Through his peer education project, he engages young refugees in West Africa to lead HIV prevention programs in their communities.
“I don’t want to see death in any age group or population caused by HIV or drug overdose again.”
Isaac Ogunkola
Ashley Rose Murphy | Canada
Ashley Murphy was 7 years old when her adoptive parents told her she was living with HIV. By age 10, Murphy began to speak publicly about living with HIV, talking to young people around the world about the stigma around HIV and how to protect and advocate for themselves. She’s been a key voice for youth activists engaged in the HIV response in Canada ever since presenting at the U.N. General Assembly and the Global Fund, and even hosting a TED Talk.
Today, Murphy is an ambassador for several foundations committed to ending the AIDS epidemic through research, government-funded programs, global advocacy, prevention, testing and treatment options. Murphy remains an inspiration for young Canadians living with or affected by HIV.
“I want everyone to know that an HIV diagnosis does not have to be the end of the world. We can continue to live healthy and fulfilling lives, but it starts with educating yourself about your diagnosis and, most importantly, being your own advocate.”
Ashley Rose Murphy
Paul Mavesere Ndhlovu | Zimbabwe
Paul Ndhlovu has been using his voice to help young people living with and vulnerable to HIV in his native Zimbabwe for years. He’s produced a peer-led radio show as the creative radio champion for Zvandiri, an organization that “connects children and young people living with HIV with peer counselors to help assure health, happiness and hope.”
In his role, Ndhlovu — together with other adolescents and young people — has created a youth-friendly environment for people living with HIV to freely discuss challenges and issues in their own lives. The show explains to young people the importance of HIV prevention behaviors, the need for increased HIV testing, their sexual and reproductive rights, and available resources to help with mental health and well-being needs.
“The Zvandiri Radio Show is such an important platform. We’re providing an open forum for people living with HIV to freely come as themselves and talk about any challenges they may face.”
Paul Mavesere Ndhlovu
Stefano Regner | Philippines
Stefano Regner’s schedule is always busy, and as a physiotherapist and sexual health advocate, his work revolves around helping others.
As a trained HIV screener, counselor, and speaker, Regner is constantly on the move — traveling across the Philippines to help link people living with HIV to immediate care and empowering people when it comes to understanding safer sex. He’s also been a research assistant for one of the Philippines’ largest grassroots HIV test-and-treat centers.
And today, as both a medical student and a social media influencer, Regner provides educational resources for people living with HIV, using health campaigns and videos.
“Social media provides a new platform and method to translate and communicate important topics about health and increasing health literacy. I enjoy sharing key information with my followers, especially as it relates to sexual and reproductive health among at-risk populations in the Philippines.”
Stefano Regner
Kalisito Biaukula | Fiji
Kalisito Biaukula’s motivation to give a voice to the voiceless and speak up for those in need is evidenced by their work across their island nation of Fiji and surrounding regions.
As an intersectional, queer, feminist activist and human rights defender, Biaukula has worked with various civil society organizations addressing intersecting human rights issues for people with diverse sexual orientations, gender identities and expressions, and sex characteristics, in Asia and the Pacific.
Biaukula is a major advocate for people living with and impacted by HIV, fighting to ensure they receive the proper care and government assistance, and calling for comprehensive sexuality education at all levels.
“It’s important for young people, especially those living in the Asia-Pacific region, to take a leading role in decisions that affect our bodies. We must all use our voices to stand up for human rights and ensure all populations are receiving equal opportunities to access care.”
Kalisito Biaukula
Sara Thapa Magar | Nepal
From a young age, Sara Magar developed an interest in social issues related to women and children living with HIV. This passion eventually led her to advocate for the needs and rights of affected populations living in the Asia-Pacific region.
Magar has been a board member of the International Community of Women Living with HIV Asia & Pacific (ICWAP) and has also spoken publicly about the need to support women-led organizations. In her current role as president of the National Federation of Women Living with HIV and AIDS (NFWLHA) in Nepal, Magar works to tackle gender inequalities and end gender-based violence.
“As youth leaders, we need to continue bringing these issues to the forefront and work to partner with the government and advocacy groups to address the challenges of women and children living with HIV.”
Sara Thapa Magar
The future is in good hands with these young leaders, advocates and activists, and we’re excited to continue to watch the impact they make on their local and global communities. To learn more about this youth-led collaboration, visit the IAS Youth Hub.
We’re accelerating our global efforts and capabilities with our new London Discovery Research Centre and U.K. headquarters
November 10, 2023
Share this article
youtube
https://www.youtube.com/watch?v=H5OyxRdSEUM
:
Using the power of leading-edge science to help save and improve lives means tapping into scientific talent around the world. That’s why we’re proud to break ground on our new London Discovery Research Centre and U.K. headquarters.
The high-profile site — located opposite King’s Cross Station in the heart of London’s Knowledge Quarter, an impressive cluster of academic, scientific and technological institutions — will be an impactful addition to our growing network of research facilities.
“Our talented discovery scientists in London are an integral part of our global research network.”
Dean Li President of MSD Research Laboratories
“Patients around the world are waiting for innovations that will help confront the tremendous burden of disease they face, and the kind of world-class scientific exploration this facility will enable is how we accelerate those innovations,” Li added.
Slated to open in 2027, the 270,000-square-foot, 10-story facility will bring together all our U.K. colleagues to help drive medical advances against some of today’s greatest health challenges.
“With the benefit of London’s thriving life sciences ecosystem and Knowledge Quarter right on our doorstep, I’m excited about the collaboration opportunities, building toward an exciting new chapter, and what this represents for employees and our partnership with the local community and beyond,” said Ben Lucas, managing director, U.K. and Ireland.
